Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 6258Carcinoma, Renal Cell 1910Urinary Bladder Neoplasms 1669Kidney Neoplasms 929Breast Neoplasms 792Neoplasms 786Carcinoma, Transitional Cell 590Carcinoma, Non-Small-Cell Lung 522Neoplasm Metastasis 510Melanoma 484Ovarian Neoplasms 466Colorectal Neoplasms 451Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 289Stomach Neoplasms 273Sarcoma 265Uterine Cervical Neoplasms 262Non-Muscle Invasive Bladder Neoplasms 262Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 202Squamous Cell Carcinoma of Head and Neck 200Wilms Tumor 196Carcinoma, Hepatocellular 195Endometrial Neoplasms 188Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 144

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dumping Syndrome × Genitourinary × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡